Can Arthroplasty Stem INfluence Outcome? (CASINO): a randomized controlled equivalence trial of 125 mm versus 150 mm Exeter V40 stems in total hip arthroplasty by Hamilton, David F et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Can Arthroplasty Stem INfluence Outcome? (CASINO): a
randomized controlled equivalence trial of 125 mm versus
150 mm Exeter V40 stems in total hip arthroplasty
Citation for published version:
Hamilton, DF, Ohly, NE & Gaston, P 2018, 'Can Arthroplasty Stem INfluence Outcome? (CASINO): a
randomized controlled equivalence trial of 125 mm versus 150 mm Exeter V40 stems in total hip
arthroplasty' Trials, vol 19, no. 1, pp. 226. DOI: 10.1186/s13063-018-2621-8
Digital Object Identifier (DOI):
10.1186/s13063-018-2621-8
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Trials
Publisher Rights Statement:
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in
any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 14. Jun. 2018
STUDY PROTOCOL Open Access
Can Arthroplasty Stem INfluence Outcome?
(CASINO): a randomized controlled
equivalence trial of 125 mm versus
150 mm Exeter V40 stems in total hip
arthroplasty
David F. Hamilton1* , Nicholas E. Ohly2 and Paul Gaston1
Abstract
Background: The use of shorter length femoral stems during total hip arthroplasty has been suggested to
accommodate wider patient femoral geometry and offer maximal bone preservation. However, cemented
short-stem designs may increase the risk of varus stem malalignment and influence patient outcomes.
Methods/Design: CASINO is a multi-centre randomised equivalence trial that will recruit 220 patients undergoing
total hip arthroplasty for osteoarthritis at two NHS hospitals in Scotland. Patients will be aged 45–80, undergoing
unilateral primary hip arthroplasty, with no plan for contralateral procedure within the study timeframe, and able to
comply with the protocol. Participants will be randomised to receive either a short (125 mm) or a standard (150 mm)
Exeter V40 stem. The Contemporary acetabular component will be used in all cases. All implants will be cemented.
Patient pain, function and satisfaction will be assessed using change from baseline measurement in Oxford Hip Score,
Forgotten Joint Score, EQ-5D, pain numerical rating scores, and patient satisfaction questionnaire at baseline and at 1
and 2 years following surgery. Radiographic assessment will evaluate stem position and will be appraised by
independent reviewers. Patients will be blind to implant allocation.
Discussion: Stem length may be associated with outcome; however, we can find no randomised trial in which
researchers investigated the effect of stem length on patient outcome following cemented total hip arthroplasty. The
aim of this trial is to determine if the use of short cemented stems offers equivalent patient outcomes to those
achieved following surgery with standard length stems.
Trial registration: International Standard Randomised Controlled Trial Number, ISRCTN13154542, Registered on
30 June 2017.
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Background
Total hip arthroplasty is one of the most successful and
cost effective of all surgical procedures in terms of allevi-
ating pain, improving quality of life and enhancing phys-
ical function [1–3]. Over 100,000 procedures were
carried out in the UK in 2016, with established implants
demonstrating 10-year survival rates of more than 95%
[4]. Various companies produce implants for hip arthro-
plasty and most have good long-term track records of
success. The orthopaedic manufacturing industry sup-
ports the continual development of implant technology
with a view to enhancing patient outcomes and prolong-
ing implant longevity.
Recent developments in hip arthroplasty have focused
on achieving the best fit in all patients through the use
of shorter femoral stems. Short stems are suggested to
eliminate problems with proximal-distal mismatch, ex-
cessive femoral bowing and diaphyseal deformity, which
can make the surgical intervention more challenging [5].
The implantation of smaller components hypothetically
also results in less damage to bone and soft tissue, and
offers preservation of bone stock, which is advantageous
in the event that future revision surgery is required. Des-
pite widespread use in clinical practice, there is a lack of
randomised trial evidence to support the potential bene-
fits of using the short stems in total hip arthroplasty [6].
The original Exeter total hip arthroplasty femoral stem
was designed in 1970 at a length of 150 mm and has
been employed successfully since. The Universal stem
was introduced in 1988, with an identical implanted por-
tion of the stem to the current design, but a different
trunnion taper. The current ‘V40’ Exeter stem design
with the V40 taper was introduced in 2001, with excel-
lent reported long-term survivorship [4, 7]. Recently,
however, it has become apparent that the design may
not be optimal for all patients. The ‘original’ 150 mm
stem may be difficult to insert in certain groups, such as
Dorr A femurs and those with excessive bow or femoral
deformity, e.g. from a previous fracture. This observation
has led to the design of a shortened Exeter V40 stem
(125 mm) for use in revision surgery with the exact
same design characteristics aside from the shorter
length. This shorter stem has been successfully
employed for revision cases and is being increasingly
used ‘off label’ in primary surgery, where the new geom-
etry allows for a better anatomical fit in some cases. The
worry is that this stem is too small and thus has too thin
a cross section, with the potential of stem fracture oc-
curring when using the revision stem in primary total
hip replacement. As a result, the manufacturer has de-
signed a range of 125 mm stem sizes that parallel the
original 150 mm length stems for use in primary sur-
gery. The new, shorter 125 mm stem range is sized at
No. 1, thus providing better stem strength whilst being
shorter to fit in Dorr A femurs. These ‘short’ stems have
been CE marked and are in routine use. However, there
are theoretical concerns that the shortened 125 mm stem
length could result in an increased incidence of varus
malalignment at the time of cementation, which in turn
may be associated with worse patient clinical outcomes.
Choy et al. [8] recently used data from the Australian
Orthopaedic Association National Joint Replacement
Registry to suggest that, at 7 years post-surgery, there is
no significant difference in the cumulative percent revi-
sion rate in the Exeter short stem (3.4%, 95% CI 2.4–4.8%)
compared with the standard length Exeter stem (3.5%,
95% CI 3.3–3.8%); however, this data does not include
patient quality of life and functional outcomes. Conse-
quently, as part of the responsible introduction of im-
plantable technology, a randomised trial comparing the
new 125 mm stem design against standard 150 mm length
stems should be conducted to ensure equivalence of out-
comes compared to the original stem design.
Methods
Study aim
The primary objective of the ‘Can Arthroplasty Stem
INfluence Outcome?’ (CASINO) study is to assess
whether using the 125 mm Exeter V40 stem in total hip
arthroplasty achieves an equivalent change in patient-
reported pain and function as the 150 mm Exeter V40
stem at 1 year. Secondary aims are to evaluate compara-
tive pre- to post-operative changes in joint-specific func-
tion, general health and health economic parameters.
Design
CASINO is a multi-centre, single blind, randomised con-
trolled equivalence trial assessing the influence of stem
length in primary total hip arthroplasty. We are conduct-
ing this study under the guidance of the Consolidated
Standards of Reporting Trials (CONSORT) Statement for
randomized controlled trials. This paper is written accord-
ing to the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Statement for report-
ing a clinical trial protocols [9] (Additional file 1).
CASINO is co-sponsored by the University of
Edinburgh & NHS Lothian (ACCORD, The Queen’s
Medical Research Institute, 47 Little France Crescent,
Edinburgh, UK). Ethical approval was granted by the
South East Scotland Research Ethics Committee 02
(reference: 16/SS/0176). The study is registered with
International Standard Randomised Controlled Trial
Number ISRCTN13154542.
Study setting
The study will be performed at two high volume NHS
orthopaedic units in Scotland, namely the Royal Infirmary
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of Edinburgh, Edinburgh, and at the Golden Jubilee
National Hospital, Clydebank.
Participants
All patients attending the routine NHS outpatient clinics
of the trial surgeons that make a decision to undergo
total hip arthroplasty and are listed for surgery will be
screened for eligibility and, if suitable, invited to partici-
pate in the trial. Written informed consent will be ob-
tained by a suitably qualified member of the research
team at study entry.
Ineligible and non-recruited patients will undergo rou-
tine total hip arthroplasty adhering to the local policy
and guidelines of the study centre.
Eligibility criteria
Inclusion criteria
The inclusion criteria are patient ages 45–80, attending
hospital for a planned primary total hip arthroplasty with
standard implants for a diagnosis of osteoarthritis who are
willing and able to comply with the study protocol.
Exclusion criteria
Exclusion criteria are dysplasia of the hip/acetabulum,
requirement for acetabular bone grafting, planned
bilateral procedures within the trial period, procedures
performed exclusively for pain relief (such as for patients
with no walking capacity) and patients with activity lim-
iting pain in either knee or contralateral hip, which
would confound the outcome assessments.
Randomisation procedures
All eligible participants will be randomised on a 1:1 ratio
to either a 125 or 150 mm Exeter V40 stem. Randomisa-
tion will be performed by a computer-generated number,
stratified by centre using random block sizes. The study
centre randomisation code is held by the local principal in-
vestigator, and consenting patients are accordingly allo-
cated to treatment arm by the local research team. Implant
group allocation is passed onto the clinical teams to coord-
inate surgery. Patients are blinded to the intervention arm.
Participants are free to withdraw from the study at any
point or a participant can be withdrawn by the investiga-
tor. If withdrawal occurs, it will be documented on a
participant ‘Change of Status’ Form. In the event of
withdrawal, patients will be invited to provide final pri-
mary end-point data.
Intervention
Patients will receive either an ‘original’ (150 mm) or
‘short’ (125 mm) Exeter stem as part of otherwise rou-
tine total hip arthroplasty at the study centres.
Procedures will be performed by consultant orthopaedic
surgeons and their supervised trainees. A standard
operative technique will be employed by all trial surgeons,
using the posterior approach, Exeter V40 femoral compo-
nent and Contemporary acetabular component (Stryker,
Mahwah, New Jersey). All implants will be cemented. The
routine post-operative patient care protocol of the study
centre will be employed.
Study outcomes and timelines
The trial primary endpoint is the comparative (between-
group) change in Oxford Hip Score (OHS) from preo-
peration baseline to 1 year postoperation. Secondary
outcomes are patient-reported outcome measures to
evaluate pre- to postoperative changes in joint-specific
function, pain, general health and health economic pa-
rameters. Radiographic evaluation will focus on stem
position and cement mantle evaluation. Clinical compli-
cations (thrombosis, dislocation, infection and failure for
any reason that results in reoperation) will be recorded.
Patient-reported outcomes
The OHS is a patient-reported outcome measure devel-
oped specifically to measure the impact of pain and func-
tional disability on an individual’s life for the population of
patients undergoing hip replacement [10]; as such, it is an
extensively validated and widely adopted outcome meas-
ure in patients undergoing hip replacement surgery and is
sensitive to detect changes over time.
The Forgotten Joint Score (FJS-12) is a patient-
reported outcome scale to assess joint awareness in hips
and knees during various activities of daily living. It uses
a 5-point Likert response format, consists of 12 ques-
tions, and the raw score is transformed to a range from
0 to 100 points. High scores indicate good outcome, i.e.
a high degree of being able to forget about the affected
joint in daily life. The FJS has a low ceiling effect and es-
pecially discriminates between good, very good and ex-
cellent outcome after total hip or total knee arthroplasty.
In its validation study, it showed high internal
consistency and discriminated well between patient
groups known to show different outcomes [11, 12].
The EQ-5D is a standardised instrument with five
items for use as a measure of self-reported general
health [13]. Applicable to a wide range of health condi-
tions and treatments, it provides a simple descriptive
profile and a single index value for health status. It is
one of the most frequently used measures to gain quality
of life scores for analysis in health economy as utility
weights for calculating the quality-adjusted life years can
be obtained.
Global hip pain severity will be assessed using an 11
point (0–10) numerical rating scale, where 0 represents
no pain and 10 the worst possible pain. The validity and
sensitivity of the numerical rating scale has been well
documented [14]. As it has been suggested that using
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multiple measurements of pain status as opposed to a
single value of ‘current pain’ may provide more realistic
and meaningful measurements of pain intensity [15],
separate assessments will be made of ‘worst pain’ and
‘perceived mean daily pain’ over the past week as has
been specifically recommended for use in osteoarthritis
clinical trials [16].
Patient satisfaction with the outcome of the study will
be evaluated with a simple question as part of the ques-
tionnaire battery. A 5-point Likert scale response format
will be employed with the options, namely very satisfied,
satisfied, neither satisfied or dissatisfied, dissatisfied and
very dissatisfied.
Radiographic evaluation
Clinical evaluation of radiographs will determine the im-
plant position by assessing varus/valgus orientation on
the antero-posterior film. The cement mantle will be
evaluated as described by Barrack et al. [17]. Length at
the hip will be assessed by evaluating a line drawn across
the inferior aspect of the obturator foramen (‘tear
drops’). Trial participant radiographs will be reviewed
and graded by two independent experts (surgeons) from
NHS Lothian. It is not possible to blind the reviewers to
allocation (this will be apparent on the radiograph). The
surgeons will review and report the films separately. In
the event of disagreement, the surgeons will discuss the
individual radiographs and reach a consensus opinion.
Femoral stem migration (in millimetres) will be
assessed using computer-assisted Einzel-Bild-Roentgen
Analyse-Femoral Component Analysis software and ra-
diographs taken at each interval. This is a well validated
method for measuring migration of total hip arthroplasty
components using standard pelvic antero-posterior ra-
diographs. A specificity of 100% and a sensitivity of 78%
compared with Roentgen stereophotogrammetric ana-
lysis for the detection of migration of over 1 mm has
been demonstrated [18].
Clinical complications
We will review for the known potential clinical compli-
cations associated with total hip replacement to ensure
balance between trial arms. These known risks include
deep vein thrombosis, dislocation, infection and failure
for any reason that results in reoperation.
Harms
As the medical devices are CE marked for this interven-
tion, there will be no formal adverse event reporting,
however, clinical complications will be reviewed as de-
scribed. If the investigator becomes aware of any serious
unexpected adverse event or reaction, this will require
expedited reporting to the sponsor by the investigator.
Re-admission for elective surgery on a different joint
does not constitute a serious adverse event or reaction.
Protocol deviations will be recorded and any influence
on outcomes incorporated into the study analysis.
Study assessment schedule
Informed consent, baseline demographics and initial
pre-operative assessment will be performed at time of
surgical pre-admission. Post-operative assessment will be
performed at 1 year clinical review or by postal ques-
tionnaire; 2 year assessment will be by postal question-
naires. Study radiographs are those routinely performed
as part of the clinical process during the hospital stay
and at 1 year post-operative clinical review (Table 1).
Analysis
Sample size
The trial will be an equivalence study, powered on the
change in the OHS that is considered clinically sig-
nificant and of interest when comparing interventions
(5 points) [19]. Data from the National Joint Registry in-
dicates that patients typically report a change of 19.7
points (SD 10.4) on the OHS.
Power calculation
A total of 94 participants are required per group to detect
a 5-point difference in the primary outcome between
groups to achieve and alpha value of 0.05 and beta value
of 0.9. Allowing for a potential 15% loss to follow-up we
are targeting a total trial recruitment of 220 participants.
Table 1 Patient visit schedule
Assessment Pre-op Inpatient 52 weeks 104 weeks
Patient consenta X
Baseline demographics X
Clinical outcomes
Oxford Hip Score X X X
Forgotten Joint Score X X X
EQ-5D X X X
Pain scores X X X
Satisfaction questionnaire X X
Clinical compilations
Complications
questionnaire
X
Case note review X
Radiographic outcomesb
Antero-posterior pelvis X X X
aConsent taken prior to any research activity
bRadiographs taken as part of routine clinical practice. The initial post-
operative radiograph is taken during the inpatient stay following the
hip replacement
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Statistical analysis
Analysis will be by intention to treat. Differences be-
tween groups will be estimated using the appropriate
methodology depending on the distribution of data,
either by t test or Wilcoxon test at the 5% significance
level to compare the distribution of the primary end-
point between the treatment samples. The patient out-
come scores will be assessed with repeated measures
analysis of variance (ANOVA) models to account for the
repeated data collection time points. Results will be pre-
sented as an adjusted mean difference with its corre-
sponding 95% confidence intervals.
Should significant data volume be missing at random,
we will incorporate a complete case analysis in addition
to intention to treat. If there are concerns as to the
balance of data in the trial arm, we will run sensitivity
analyses. Subgroup analysis is planned by femur type
(Dorr classification). Any further subgroup analysis will
be post-hoc and clearly labelled as such. A data analysis
plan will be finalised prior to data lock and the analysis
will be conducted blind to intervention allocation.
Data management
Each site will hold data according to the Data Protection
Act 1998, and data will be collated in case report forms
identified by a unique identification number only. Re-
cruitment logs at the sites will list the identification
numbers. All data recorded electronically will be held on
password-protected NHS trust information technology
systems with permission for access as detailed in the
delegation log. All study files will be stored in accord-
ance with Good Clinical Practice guidelines. Study docu-
ments held by the sponsor will be retained in a secure,
locked location for the duration of the trial. All essential
documents, including source documents, will be
retained for a minimum period of 5 years after study
completion. All work will be conducted following NHS
trust data protection policy.
In order to eliminate possible data entry errors, individ-
ual data will be compared to a range of plausible values.
After data entry, random checks will be performed to
search for internal inconsistencies, range errors or missing
data. The assessors and data entry personnel will undergo
training prior to the start of CASINO.
Monitoring
Investigators and institutions involved in the study will
permit trial-related monitoring and audits on behalf of
the sponsor, Research Ethics Committee review and
regulatory inspection(s). In the event of an audit or
monitoring, the Investigator agrees to allow the repre-
sentatives of the sponsor direct access to all study
records and source documentation. In the event of
regulatory inspection, the Investigator agrees to allow
inspectors direct access to all study records and source
documentation.
Protocol amendments
Amendments to the protocol must be submitted in writ-
ing to the appropriate Research Ethics Committee,
Regulatory Authority and local research and develop-
ment for approval prior to participants being enrolled
into an amended protocol.
Discussion
The primary aim of CASINO is to evaluate whether dif-
ferences in the length of femoral stem used results in
differences in patient outcomes following total hip
arthroplasty. The Exeter V40 is the dominant brand of
cemented femoral stem used in the UK with greater than
60% of market share [20]. The stem range has been ex-
panded to include short stem options. Whilst national
joint registries collect data regarding the implantable de-
vices, the granularity of implant data is variable and few
routinely collate patient outcome scores. To our know-
ledge, there is no randomized trial evidence to evaluate
whether the outcome of 125 mm short stem procedures
are equivalent to those following procedures carried with
the original 150 mm stem length.
Strengths and limitations
CASINO benefits from the use of a variety of outcome
metrics. We are collecting the OHS and EQ-5D as these
are the mainstay of outcome analysis following total hip
arthroplasty in the UK and this facilitates wider com-
parative interpretation. These questionnaires are aug-
mented by the use of more sensitive and discriminative
metrics. The FJS-12 has proven to be a more responsive
tool, with greater measurement range, improved dis-
criminative ability and effect size compared to the OHS
[21]. Pain intensity is evaluated with direct evaluation of
that construct using multiple rating scales. Radiographic
review will directly evaluate any difference in position of
the stem.
Patient outcome metrics can be influenced by dysfunc-
tion in the contralateral limb, and as such we aim to en-
sure that the patients taking part in CASINO are not
suffering symptomatic bilateral joint disease that would
likely result in both hips being replaced within the study
timeframe. This inclusion criteria enhances the validity
of the study outcomes; however, it may compromise the
generalisability of the findings. CASINO has been de-
signed to investigate short-term clinical and patient-
reported outcomes, however, the longer term metric of
the success of an implant is longevity and surgical revi-
sion rate. 95% implant survival at 10 years is expected of
all modern prostheses and such evaluation is outside the
scope of this study. However, to facilitate future longer
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term evaluation, of this study cohort we have caped the
age of participants to CASINO at 80 years. This inclu-
sion criterion many also somewhat limit generalisability.
The results of this trial will be presented at scientific
meetings and submitted for publication in relevant peer-
reviewed journals. Results will be made available to
patients on the public facing website of the trial centres.
Published results will not contain any patient-
identifiable data and will be presented for the whole
group rather than for individual participants.
Trial status
CASINO opened to recruitment on the July 1, 2017.
Data collection is ongoing with an anticipated recruit-
ment end date of June 29, 2018.
Additional file
Additional file 1: SPIRIT checklist. (PDF 236 kb)
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